Xilio Therapeutics Shareholders Approve Flexible Reverse Stock Split

The latest update is out from Xilio Therapeutics ( (XLO) ).

On February 23, 2026, Xilio Therapeutics, Inc. held a special meeting of stockholders at which investors approved an amendment to the company’s restated certificate of incorporation to enable a reverse stock split of its common shares at a ratio to be set between 1-for-2 and 1-for-30 by the board of directors. This approval gives the board flexibility to adjust the share count and potentially support the company’s stock price without returning to shareholders for another vote, and stockholders also backed a proposal to adjourn the meeting if needed for additional proxy solicitation related to the reverse split.

The most recent analyst rating on (XLO) stock is a Hold with a $0.59 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.

Spark’s Take on XLO Stock

According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.

The score is primarily held back by weak financial fundamentals (large losses, ongoing cash burn, and negative equity) despite strong recent revenue growth. Technicals are mixed with a weak longer-term trend but neutral-to-stable near-term momentum. Corporate events improve the outlook by extending cash runway into 2027, while valuation is constrained by a negative P/E and no dividend data.

To see Spark’s full report on XLO stock, click here.

More about Xilio Therapeutics

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies. The company targets cancer indications where precision activation of immune therapies within the tumor microenvironment may improve efficacy and reduce systemic toxicity for patients and healthcare providers.

Average Trading Volume: 468,494

Technical Sentiment Signal: Sell

Current Market Cap: $41.93M

For an in-depth examination of XLO stock, go to TipRanks’ Overview page.